PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30514344-4 2018 In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. cabozantinib 201-213 fms related receptor tyrosine kinase 3 Homo sapiens 74-78 30587441-1 2019 INTRODUCTION: Cabozantinib is a receptor tyrosine kinases inhibitor that targets MET (c-MET), VEGF receptor 2 (VEGFR2), RET, AXL, KIT, FLT-3, and TIE-2 and previously showed promising single agent activity in recurrent ovarian cancer. cabozantinib 14-26 fms related receptor tyrosine kinase 3 Homo sapiens 135-140 29662541-1 2018 Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma (RCC), next to vascular endothelial growth factor receptor 2, KIT, FLT3 and RET. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 233-237 28960265-0 2018 Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 108-112 28960265-1 2018 BACKGROUND: Cabozantinib, a tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is approved for use in multiple malignancies. cabozantinib 12-24 fms related receptor tyrosine kinase 3 Homo sapiens 57-83 28960265-14 2018 CONCLUSIONS: Cabozantinib is well tolerated in AML patients at an MTD of 40 mg daily and is a potent inhibitor of FLT3/ITD- and F691 TKD-altered tyrosine kinases. cabozantinib 13-25 fms related receptor tyrosine kinase 3 Homo sapiens 114-118 29727493-1 2018 Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 108-112 30069760-1 2018 Cabozantinib is a receptor tyrosine kinase inhibitor (TKI) with activity against a broad range of targets, including MET, RET, AXL, VEGFR2, FLT3, and c-KIT. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 140-144 24756794-1 2014 Cabozantinib is a receptor tyrosine kinase inhibitor with activity against MET, VEGFR2, FLT3, c-KIT, and RET. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 88-92 26536165-1 2016 Cabozantinib (XL-184) is a potent inhibitor of MET, VEGFR 2/KDR, RET and other receptor tyrosine kinases, such as KIT, AXL and FLT3. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 127-131 26536165-1 2016 Cabozantinib (XL-184) is a potent inhibitor of MET, VEGFR 2/KDR, RET and other receptor tyrosine kinases, such as KIT, AXL and FLT3. cabozantinib 14-20 fms related receptor tyrosine kinase 3 Homo sapiens 127-131 28703624-3 2017 Cabozantinib is oral, small-molecule tyrosine kinase inhibitor that primarily targets MET, VEGFR2, AXL and RET, with additional effect on KIT and FLT3. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 146-150 27842445-1 2017 Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 89-93 27060207-0 2016 Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 75-79 27060207-0 2016 Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD). cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 109-113 27060207-2 2016 We found that cabozantinib was significantly cytotoxic to MV4-11 and Molm-13 cells that harbored FLT3-ITD, resulting in IC50 values of 2.4 nM and 2.0 nM, respectively. cabozantinib 14-26 fms related receptor tyrosine kinase 3 Homo sapiens 97-101 27060207-3 2016 However, K562, OCI-AML3 and THP-1 (leukemia cell lines lacking FLT3-ITD) were resistant to cabozantinib, showing IC50 values in the micromolar range. cabozantinib 91-103 fms related receptor tyrosine kinase 3 Homo sapiens 63-67 27060207-4 2016 Cabozantinib arrested MV4-11 cell growth at the G0/G1 phase within 24 h, which was associated with decreased phosphorylation of FLT3, STAT5, AKT and ERK. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 128-132 27060207-6 2016 Thus, cabozantinib is selectively cytotoxic to leukemia cells with FLT3-ITD, causing cell-cycle arrest and apoptosis. cabozantinib 6-18 fms related receptor tyrosine kinase 3 Homo sapiens 67-71 27060207-8 2016 Clinical trials evaluating the efficacy of cabozantinib in acute myeloid leukemia (AML) with FLT3-ITD are warranted. cabozantinib 43-55 fms related receptor tyrosine kinase 3 Homo sapiens 93-97 26152149-1 2015 Cabozantinib is an oral once-daily multitarget tyrosine kinase inhibitor of MET, VEGFR2, RET, acting against KIT, AXL, FLT3 and Tie-2. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 119-123 21926191-3 2011 Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 258-262 21926191-3 2011 Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3. cabozantinib 14-19 fms related receptor tyrosine kinase 3 Homo sapiens 258-262 34944800-8 2021 Interestingly, ispinesib and cabozantinib prevent activation of AXL, a key driver and mechanism of drug resistance in FLT3-ITD+ AML patients. cabozantinib 29-41 fms related receptor tyrosine kinase 3 Homo sapiens 118-122 34944800-10 2021 Together, we suggest WS6, ispinesib, ponatinib and cabozantinib as novel options for targeting FLT3-ITD+ AML. cabozantinib 51-63 fms related receptor tyrosine kinase 3 Homo sapiens 95-99 34117374-1 2021 Cabozantinib is a potent tyrosine kinase inhibitor with multiple targets including MET, VEGFR2, RET, KIT, and FLT3. cabozantinib 0-12 fms related receptor tyrosine kinase 3 Homo sapiens 110-114 34117374-3 2021 We recently suggested cabozantinib as a potential therapeutic alternative for acute myeloid leukemia (AML) patients with FLT3-internal tandem duplication (FLT3-ITD). cabozantinib 22-34 fms related receptor tyrosine kinase 3 Homo sapiens 121-125 34117374-3 2021 We recently suggested cabozantinib as a potential therapeutic alternative for acute myeloid leukemia (AML) patients with FLT3-internal tandem duplication (FLT3-ITD). cabozantinib 22-34 fms related receptor tyrosine kinase 3 Homo sapiens 155-159